QuidelOrtho reports third quarter revenue of $700 million and adjusted diluted EPS of $0.80
Reuters
Nov 06
QuidelOrtho reports third quarter revenue of $700 million and adjusted diluted EPS of $0.80
QuidelOrtho Corporation reported third quarter 2025 total revenue of $700 million, a 4.0% decrease compared to $727 million in the prior year period. Non-respiratory revenue was $588 million, up 5.0% as reported and 4.0% in constant currency; excluding Donor Screening, non-respiratory revenue grew 6.0% in constant currency. Labs revenue grew 5.0% as reported and 4.0% in constant currency. Respiratory revenue was $112 million, with the decline primarily due to a 63.0% decrease in COVID-19 revenue. GAAP operating expenses decreased by 6.0%, and non-GAAP operating expenses decreased by 7.0%. The period included a $701 million non-cash goodwill impairment charge, resulting in a GAAP net loss margin of (105%) and a GAAP operating margin of (101%). Adjusted EBITDA margin was 25.0%, a 180 basis point increase compared to the prior year. GAAP diluted loss per share was $10.78, while adjusted diluted earnings per share were $0.80. The company completed a debt refinancing during the quarter, improving financial flexibility.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quidelortho Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: LA15870) on November 05, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.